Sparstolonin B nano-formulation attenuates LPS-induced lung injury
nSsnB demonstrates less toxicity than free SsnB and attenuates the effects of LPS on inflammation in RAW264.7 cells. Prophylactic nSsnB attenuates LPS-induced ALI by reducing inflammation via MyD88/NF-κB signaling pathways. Collectively these findings support the therapeutic potential of nano-formulated nSsnB for ALI treatment.
Authors
- Juntao Luo (ORCID: https://orcid.org/0000-0002-3538-9453)
- Xiguang Yang (ORCID: https://orcid.org/0000-0001-6447-6188)
- Changying Shi
- Adam M. Novak (ORCID: https://orcid.org/0000-0001-5828-047X)
- Robert N. Cooney (ORCID: https://orcid.org/0000-0002-8901-3638)
- Xiaojing Wang (ORCID: https://orcid.org/0000-0001-6848-8688)
- Qinghe Meng
- Hui Zhang (ORCID: https://orcid.org/0000-0002-5426-2140)
- Dandan Guo (ORCID: https://orcid.org/0000-0002-6829-1356)
Institutions
- SUNY Upstate Medical University (US)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-08
- DOI
- https://doi.org/10.3389/fphar.2025.1532391
- Citations
- 2
- Primary Topic
- Neonatal Respiratory Health Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- National Institutes of Health
- National Institute of General Medical Sciences